[Role of monoclonal anti-IgE antibodies (rhu-MAb) in the treatment of allergic bronchial asthma].
The key role in the mechanism of immune response to allergenic exposure in bronchial asthma is played by immunoglobulins E (IgE), which bind to specific Fce receptors on mast cells, basophils, B-lymphocytes and eosinophils. The specific recombinant human monoclonal antibodies (rhu-MAb) directed against free IgE are a new promising therapeutic remedy for symptoms of allergic asthma. In this article the review of clinical studies concerning the usefulness of rhu-MAb in treatment of bronchial asthma is presented.
Targowski
Tomasz
T
Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii, Centralnego Szpitala Klinicznego WAM w Warszawie.
From
Sławomir
S
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D001402:B-Lymphocytes / Q000276:immunology; D001491:Basophils / Q000276:immunology; D004804:Eosinophils / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D008407:Mast Cells / Q000276:immunology; D012130:Respiratory Hypersensitivity / Q000188:drug therapy
D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; C401983:rhuMAb-E25; D007073:Immunoglobulin E
Znaczenie przeciwciał monoklonalnych anty-IgE w leczeniu alergicznej astmy oskrzelowej.